Abstract
Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma patients. Of the 38 evaluable patients, 30 (80%) were rituximab-refractory. The overall response rate (ORR) was 32%, with six complete responses (CR) and six partial responses (PR). The median time to progression for responders was 8 months (range: 2-36+); two patients with rituximab-refractory follicular lymphoma were in CR at 25 and 36+ months. The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon.
Publication types
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Diphtheria Toxin / therapeutic use*
-
Female
-
Humans
-
Interleukin-2 / therapeutic use*
-
Lymphoma, B-Cell / drug therapy*
-
Lymphoma, B-Cell / pathology
-
Lymphoma, Follicular / drug therapy
-
Lymphoma, Follicular / pathology
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Recombinant Fusion Proteins / therapeutic use
-
Recurrence
-
Rituximab
-
Time Factors
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Diphtheria Toxin
-
Interleukin-2
-
Recombinant Fusion Proteins
-
denileukin diftitox
-
Rituximab